Streetbeat News

TRDA

Entrada Therapeutics, Inc.

https://www.entradatx.com

Industry

Biotechnology

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Open

17.84

Mkt cap

653M

Volume

106K

High

18.02

P/E Ratio

12.12

52-wk high

20.49

Low

17.40

Div yield

N/A

52-wk low

10.75

Entrada Therapeutics reported a Q1 2024 GAAP EPS of $0.68, which may not be comparable to the estimated $(0.52), and sales of $59.120M, also not comparable to the estimated $14.977M.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:26 am

In Thursday's after-market session, several health care stocks showed significant movement. Ontrak, Ocuphire Pharma, and Lyell Immunopharma were among the top gainers, with Ontrak leading at an 18.7% increase. Conversely, Motus GI Holdings, Acorda Therapeutics, and Nurix Therapeutics were the top losers, with Motus GI Holdings experiencing a 32.6% decline. Notably, Nurix Therapeutics' drop was following their Q1 earnings report.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 8:31 pm

Insiders at HCI Group, America's Car-Mart, and Entrada Therapeutics have made notable purchases of their company's stock, signaling confidence in their respective companies' futures. HCI Group's CEO acquired shares at an average price of $114.90, with an analyst maintaining an Outperform rating and a $140 price target. America's Car-Mart's CEO purchased shares at $61.62, despite an analyst maintaining an Underperform rating with a lowered price target. Entrada Therapeutics saw purchases by a director at an average price of $13.57, following upbeat quarterly sales.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 10:41 am

Insiders have made notable purchases in Cardlytics, Phunware, Energy Services of America, and Entrada Therapeutics, signaling confidence in these companies. Cardlytics' insider bought shares worth around $4.96 million, while Phunware's CFO, Energy Services of America's Director, and Entrada Therapeutics' Director also made significant purchases. These actions may indicate a bullish outlook for these stocks.

Portfolio Pulse from Avi Kapoor

March 22, 2024 | 11:29 am

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Entrada Therapeutics (NASDAQ:TRDA) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 10:38 am

Entrada Therapeutics (NASDAQ:TRDA) reported Q4 earnings with a significant miss on estimated earnings by -71.0%, posting an EPS of $-0.29 against an estimate of $-0.17. However, revenue saw an increase of $41.85 million from the same period last year. Despite beating EPS estimates last quarter, the share price dropped by 1.0% the following day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 1:35 pm

Entrada Therapeutics announced its cash balance of $352M, extending its cash runway through Q2 2026. This financial stability is crucial for its ongoing and future projects.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:22 am

Entrada Therapeutics (TRDA) reported a Q4 GAAP EPS of $(0.29), missing the $(0.17) estimate, but sales of $41.85M exceeded the $23.69M estimate. The EPS loss improved by 63.29% from the previous year, while sales significantly outperformed expectations.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:21 am

Entrada Therapeutics' stock price has risen following Oppenheimer's initiation of coverage with an Outperform rating and a $22 price target.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 6:51 pm

Oppenheimer analyst Hartaj Singh has initiated coverage on Entrada Therapeutics (NASDAQ:TRDA) with an Outperform rating and set a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:23 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.